221 related articles for article (PubMed ID: 20402753)
1. Epstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosis.
Lindsey JW; Hatfield LM; Vu T
Eur J Neurol; 2010 Oct; 17(10):1263-9. PubMed ID: 20402753
[TBL] [Abstract][Full Text] [Related]
2. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.
Farrell RA; Antony D; Wall GR; Clark DA; Fisniku L; Swanton J; Khaleeli Z; Schmierer K; Miller DH; Giovannoni G
Neurology; 2009 Jul; 73(1):32-8. PubMed ID: 19458321
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus and disease activity in multiple sclerosis.
Buljevac D; van Doornum GJ; Flach HZ; Groen J; Osterhaus AD; Hop W; van Doorn PA; van der Meché FG; Hintzen RQ
J Neurol Neurosurg Psychiatry; 2005 Oct; 76(10):1377-81. PubMed ID: 16170080
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study.
Ascherio A; Munger KL; Lennette ET; Spiegelman D; Hernán MA; Olek MJ; Hankinson SE; Hunter DJ
JAMA; 2001 Dec; 286(24):3083-8. PubMed ID: 11754673
[TBL] [Abstract][Full Text] [Related]
5. Heightened Epstein-Barr virus immunity and potential cross-reactivities in multiple sclerosis.
Thomas OG; Haigh TA; Croom-Carter D; Leese A; Van Wijck Y; Douglas MR; Rickinson A; Brooks JM; Taylor GS
PLoS Pathog; 2024 Jun; 20(6):e1012177. PubMed ID: 38843296
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Epstein-Barr virus-specific antibodies in Cypriot multiple sclerosis patients.
Deeba E; Koptides D; Gaglia E; Constantinou A; Lambrianides A; Pantzaris M; Krashias G; Christodoulou C
Mol Immunol; 2019 Jan; 105():270-275. PubMed ID: 30562647
[TBL] [Abstract][Full Text] [Related]
7. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis.
Jilek S; Schluep M; Meylan P; Vingerhoets F; Guignard L; Monney A; Kleeberg J; Le Goff G; Pantaleo G; Du Pasquier RA
Brain; 2008 Jul; 131(Pt 7):1712-21. PubMed ID: 18550621
[TBL] [Abstract][Full Text] [Related]
8. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
JAMA; 2005 May; 293(20):2496-500. PubMed ID: 15914750
[TBL] [Abstract][Full Text] [Related]
9. Multiple sclerosis: the elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1.
Ruprecht K; Wunderlich B; Gieß R; Meyer P; Loebel M; Lenz K; Hofmann J; Rosche B; Wengert O; Paul F; Reimer U; Scheibenbogen C
J Neuroimmunol; 2014 Jul; 272(1-2):56-61. PubMed ID: 24798244
[TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis and Epstein-Barr virus.
Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
JAMA; 2003 Mar; 289(12):1533-6. PubMed ID: 12672770
[TBL] [Abstract][Full Text] [Related]
11. No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis.
Jafari N; van Nierop GP; Verjans GM; Osterhaus AD; Middeldorp JM; Hintzen RQ
J Clin Virol; 2010 Sep; 49(1):26-31. PubMed ID: 20638898
[TBL] [Abstract][Full Text] [Related]
12. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study.
Sundström P; Juto P; Wadell G; Hallmans G; Svenningsson A; Nyström L; Dillner J; Forsgren L
Neurology; 2004 Jun; 62(12):2277-82. PubMed ID: 15210894
[TBL] [Abstract][Full Text] [Related]
13. Serologic Response to the Epstein-Barr Virus Peptidome and the Risk for Multiple Sclerosis.
Cortese M; Leng Y; Bjornevik K; Mitchell M; Healy BC; Mina MJ; Mancuso JD; Niebuhr DW; Munger KL; Elledge SJ; Ascherio A
JAMA Neurol; 2024 May; 81(5):515-524. PubMed ID: 38497939
[TBL] [Abstract][Full Text] [Related]
14. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel.
Munger KL; Levin LI; O'Reilly EJ; Falk KI; Ascherio A
Mult Scler; 2011 Oct; 17(10):1185-93. PubMed ID: 21685232
[TBL] [Abstract][Full Text] [Related]
15. Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis.
Waubant E; Mowry EM; Krupp L; Chitnis T; Yeh EA; Kuntz N; Ness J; Belman A; Milazzo M; Gorman M; Weinstock-Guttman B; Rodriguez M; James JA
Mult Scler; 2013 Jun; 19(7):891-5. PubMed ID: 23232601
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus reactivation and multiple sclerosis.
Torkildsen Ø; Nyland H; Myrmel H; Myhr KM
Eur J Neurol; 2008 Jan; 15(1):106-8. PubMed ID: 18042233
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samples.
Salzer J; Nyström M; Hallmans G; Stenlund H; Wadell G; Sundström P
Mult Scler; 2013 Oct; 19(12):1587-91. PubMed ID: 23549431
[TBL] [Abstract][Full Text] [Related]
18. Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model.
Jog NR; McClain MT; Heinlen LD; Gross T; Towner R; Guthridge JM; Axtell RC; Pardo G; Harley JB; James JA
J Autoimmun; 2020 Jan; 106():102332. PubMed ID: 31515129
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus neutralizing antibody levels and risk of multiple sclerosis.
Simon KC; O'Reilly EJ; Munger KL; Finerty S; Morgan AJ; Ascherio A
Mult Scler; 2012 Aug; 18(8):1185-7. PubMed ID: 22291034
[TBL] [Abstract][Full Text] [Related]
20. Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.
Sisay S; Lopez-Lozano L; Mickunas M; Quiroga-Fernández A; Palace J; Warnes G; Alvarez-Lafuente R; Dua P; Meier UC
J Neuroimmunol; 2017 May; 306():40-45. PubMed ID: 28385186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
